Summary
Unable to verify most claims against the supplied label excerpt, which contains only section headings and partial adverse-reaction topic cross-references. Several claims are therefore unsupported/unassessable due to missing FDA-label text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is discussed as having adverse reactions related to infections, hypersensitivity reactions, inflammatory bowel disease, and eczematous eruptions (as topics referenced in Warnings and Precautions cross-references).
ADVERSE REACTIONS partial excerpt lists: Infections [see Warnings and Precautions (5.1)], Hypersensitivity Reactions [see Warnings and Precautions (5.2)], Inflammatory Bowel Disease [see Warnings and Precautions (5.4)], Eczematous Eruptions [see Warnings and Precautions (5.5)].
Unsupported Statements
Cosentyx is a biologic medication used to treat autoimmune diseases including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
No substantive INDICATIONS AND USAGE text was provided in the prompt (only the section heading).
Cosentyx works by blocking the action of interleukin-17A.
No substantive CLINICAL PHARMACOLOGY text was provided (only the section heading).
Cosentyx can suppress the immune system.
No substantive WARNINGS/PRECAUTIONS or CLINICAL PHARMACOLOGY text about immune suppression was provided.
Live vaccines should not be administered to individuals taking immunosuppressive therapies, including biologics like Cosentyx.
No substantive WARNINGS AND PRECAUTIONS text was provided (only the section heading).
The immune system is weakened with immunosuppressive therapies such as Cosentyx, making it more challenging for the body to respond to live vaccines.
No substantive WARNINGS/PRECAUTIONS or related mechanism text was provided.
The manufacturer of Cosentyx recommends that patients avoid live vaccines while taking the medication.
No manufacturer-recommendation wording was provided from the label.
The prescribing information for Cosentyx states that live vaccines should be avoided for at least 4 weeks before and 4 weeks after treatment with Cosentyx.
No vaccination timing language was provided from the label excerpt.
Receiving live vaccines while on biologics like Cosentyx can increase the risk of complications from live vaccines.
No substantive WARNINGS/PRECAUTIONS text was provided.
Inactivated vaccines are generally safe to receive while taking Cosentyx.
No substantive vaccine-related guidance was provided.
Etanercept (Enbrel) is an example of another biologic that may allow live vaccines to be administered while on treatment.
The prompt provides no label text comparing other biologics or stating any allowance for live vaccines with etanercept.
At least 4 weeks after stopping Cosentyx, it is recommended to wait before receiving live vaccines.
No substantive vaccination timing language was provided from the label excerpt.
Contradictions
Low
AI Statement
Cosentyx can suppress the immune system.
Label Reference
Not verifiable: no substantive WARNINGS/PRECAUTIONS or CLINICAL PHARMACOLOGY provided to confirm or refute immune-suppression wording.
Low
AI Statement
Inactivated vaccines are generally safe to receive while taking Cosentyx.
Label Reference
Not verifiable: no substantive vaccine-related language provided.
Low
AI Statement
Etanercept (Enbrel) is an example of another biologic that may allow live vaccines to be administered while on treatment.
Label Reference
Not verifiable: no comparative statements or etanercept-specific guidance provided.
Important Omissions
Boxed warning / contraindications language, if any, from the FDA label (not provided).
Importance:
Moderate
Actual Cosentyx vaccine-related statements (including contraindications/warnings about live vaccines and specific timing such as 4 weeks) from WARNINGS AND PRECAUTIONS and/or DOSAGE AND ADMINISTRATION (not provided).
Importance:
Moderate
Dose, administration, and monitoring instructions (not provided).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Most safety-critical vaccine timing/immune-effects claims cannot be validated against the provided label excerpt; however, no explicit contraindication or dosing error claims were provided beyond vaccine avoidance/timing statements which remain unassessable.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unverifiable
Primary Issue
The prompt does not include substantive FDA-label text for indications, clinical pharmacology, or vaccine-related warnings/timing; therefore most claims cannot be confirmed.
Suggested Improvement
Provide the actual FDA label sections (Indications and Usage, Clinical Pharmacology, Warnings/Precautions related to vaccinations, and any specific timing guidance, plus Contraindications/Dosing/Special Populations) so each vaccine/immune-mechanism statement can be directly audited.